INDICATIONS

FULL PRESCRIBING INFORMATION

PATIENT INFORMATION

VISIT HEALTHCARE PROFESSIONAL SITE
A potential KRAZATI® patient dressed in a patterned jumpsuit and cardigan against a blue background.
A potential KRAZATI® patient dressed in a patterned jumpsuit and cardigan against a blue background.

About
KRAS G12C

 

 

Not an actual patient.

About KRAS G12C In CRC

Cell mutations can lead to the development of CRC.

Cancer that starts in the tissues of the colon is called colon cancer, and cancer that starts in the rectum is called rectal cancer. Cancer that affects either of these parts may also be called colorectal cancer, or CRC for short. 

People with cancer can have changes to one or more genes in a cell that cause it to not work properly. These mutations lead to abnormal growth of cells. 

The growth and development of cells can be controlled by genes like KRAS. When KRAS is mutated, this can set off a domino effect that can lead to cancer. The KRAS G12C mutation is one of many mutations that may be found in CRC.

KRAS mutations are among the most common mutations found in CRC, and about 1 in 30 people with CRC have the KRAS G12C mutation.

1 out of 30 people with colorectal cancer have the KRAS G12C mutation.

KRAS works like an on/off switch

sl
KRAS is a gene that
makes a protein
sl
This protein works like
an on/off switch
sl
KRAS G12C can make
the switch stay “on”
sl
About Biomarker Testing

Your cancer may have biomarkers that can be identified through testing.

Biomarker testing is a way to look for genes and proteins that can provide information about cancer. Each person’s cancer has a unique pattern of biomarkers. Knowing your mutation status can help your doctor find the best treatment approach for you.  

Ask your doctor to test for KRAS G12C to determine your mutation status. Your doctor may have already tested you when you were first diagnosed and can look back to check for KRAS G12C.

CRC=colorectal cancer.

-

Get an understanding of your biomarker mutations and use that to make sure you find the best possible treatment approach.”

KRAZATI TRIAL PARTICIPANT

-

KRAZATI is designed to suppress KRAS G12C tumor growth. Learn how KRAZATI works >

IMPORTANT SAFETY INFORMATION

KRAZATI may cause serious side effects, including stomach and intestinal (gastrointestinal) problems, changes in the electrical activity of the heart called QTc prolongation, liver problems, and lung or breathing problems.

Before taking KRAZATI, tell your healthcare provider about all of your medical conditions, including if you:

 
  • have any heart problems, including heart failure and congenital long QT syndrome
  • have liver problems
  • are pregnant or plan to become pregnant. It is not known if KRAZATI can harm your unborn baby
  • are breastfeeding or plan to breastfeed. It is not known if KRAZATI passes into your breastmilk. Do not breastfeed during treatment and for 1 week after your last dose of KRAZATI

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. KRAZATI can affect the way other medicines work, and other medicines can affect how KRAZATI works.

KRAZATI can cause serious side effects, including:

 
  • Stomach and intestinal (gastrointestinal) problems. Stomach and intestinal side effects including nausea, diarrhea, or vomiting, are common with KRAZATI but can also sometimes be severe. KRAZATI can also cause serious stomach and intestinal side effects such as bleeding, obstruction, inflammation of the colon (colitis), and narrowing (stenosis)

    • Call your healthcare provider if you develop any of the signs or symptoms of stomach or intestinal problems listed above during treatment with KRAZATI

    • Your healthcare provider may prescribe an antidiarrheal medicine or anti-nausea medicine, or other treatment, as needed
       
  • Changes in the electrical activity of your heart called QTc prolongation. Certain changes can occur in the electrical activity of your heart during treatment with KRAZATI, and can be seen on a test called an electrocardiogram (ECG or EKG). QTc prolongation can increase your risk for irregular heartbeats that can be life-threatening, such as torsades de pointes, and can lead to sudden death

    • You should not take KRAZATI if you have congenital long QT syndrome or if you currently have QTc prolongation. See “Before taking KRAZATI, tell your healthcare provider about all of your medical conditions, including if you:”

      • Your healthcare provider should monitor the electrical activity of your heart and the levels of body salts in your blood (electrolytes) especially potassium and magnesium before starting and during treatment with KRAZATI if you have heart failure, a slow heart rate, abnormal levels of electrolytes in your blood, or if you take a medicine that can prolong the QT interval of your heartbeat

      • Tell your healthcare provider if you feel dizzy, lightheaded, or faint, or if you get abnormal heartbeats during treatment with KRAZATI
  • Liver problems. Abnormal liver blood test results are common with KRAZATI and can sometimes be severe. Your healthcare provider should do blood tests before starting and during treatment with KRAZATI to check your liver function. Tell your healthcare provider right away if you develop any signs or symptoms of liver problems, including:

    • your skin or white part of your eyes turns yellow (jaundice), dark or “tea-colored” urine, light-colored stools (bowel movements), tiredness or weakness, nausea or vomiting, bleeding or bruising, loss of appetite, pain, aching, or tenderness on the right side of your stomach area (abdomen)
       
  • Lung or breathing problems. KRAZATI may cause inflammation of the lungs that can lead to death. Tell your healthcare provider or get emergency medical help right away if you have new or worsening shortness of breath, cough, or fever

The most common side effects

 
  • The most common side effects of KRAZATI when used alone for NSCLC include: nausea, diarrhea, vomiting, tiredness, muscle and bone pain, kidney problems, swelling, decreased appetite, trouble breathing

  • The most common side effects when KRAZATI is used in combination with cetuximab for CRC include: skin rash, nausea, diarrhea, vomiting, tiredness, muscle and bone pain, headache, dry skin, stomach pain, decreased appetite, swelling, low red blood cell count, cough, dizziness, constipation, nerve damage in the arms and legs

Certain abnormal blood test results are common during treatment with KRAZATI, when used alone or in combination with cetuximab. Your healthcare provider will monitor you for abnormal blood tests and treat you if needed.

KRAZATI may cause fertility problems in males and females, which may affect your ability to have children. Talk to your healthcare provider if this is a concern for you.

These are not all the possible side effects of KRAZATI. Call your doctor for medical advice about side effects. You may report side effects to the FDA. Visit  fda.gov/medwatch, or call 1-800-FDA-1088. You may also report side effects to 1-844-647-2841.

Please see KRAZATI Patient Information. 

1914-US-2400473  10/24 

Bristol Myers Squibb logo

Site Map     Legal Notice     Privacy Policy     Your Privacy Choices    

© 2024 Mirati Therapeutics, Inc., a Bristol Myers Squibb company.
KRAZATI® and the related logo are registered trademarks of Mirati Therapeutics, Inc.

This website is intended for U.S. residents 18 years of age or older.

1914-US-2400471 10/24